Mc-VC-PAB-SN38 CAS:1801838-28-7 is a novel chemical compound that belongs to the class of antibody-drug conjugates (ADCs). It consists of a cytotoxic agent, SN38, linked to a monoclonal antibody via a linker molecule containing functional groups, Mc-VC-PAB.
The linker molecule, Mc-VC-PAB, contains several functional groups, including a maleimide group (-COCH=CH-), a valine-citrulline dipeptide, and a para-aminobenzyloxycarbonyl (PAB) group. The maleimide group enables the selective conjugation of Mc-VC-PAB-SN38 to thiol-containing biomolecules, such as monoclonal antibodies. The valine-citrulline dipeptide enhances the stability and solubility of the conjugate, while the PAB group provides a site for further modifications, such as the attachment of polyethylene glycol (PEG) chains, to improve pharmacokinetics.
Mc-VC-PAB-SN38 has been extensively investigated in the field of oncology as a promising therapeutic agent for the treatment of various solid tumors, including breast, lung, and ovarian cancer. The monoclonal antibody component of Mc-VC-PAB-SN38 selectively targets cancer cells expressing a specific surface antigen, while the SN38 component induces cytotoxicity by inhibiting DNA topoisomerase I. The use of a targeted approach minimizes off-target toxicity and enhances the efficacy of the drug.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.